During the corresponding time, Livanova Plc recorded a revenue increase by 10.8 % year on year, sequentially revenue grew by 7.97 %. While revenue at the Livanova Plc's corporate clients
Livanova Plc's Comment on Sales, Marketing and Customers
LivaNova serves a global customer base that includes perfusionists, neurologists, neurosurgeons, other healthcare professionals, hospitals, and medical institutions. The company collaborates with medical professionals to monitor therapeutic and diagnostic trends and participates in medical conferences and training activities. Hospitals and medical device customers often seek to reduce costs through centralized purchasing and vendor consolidation, resulting in competitive pricing pressures. LivaNova operates in over 100 countries and faces competition from large and small manufacturers, alternative medical therapies, pharmaceuticals, and surgical interventions. Key competitive factors include product efficacy, quality, price, managed care developments, and healthcare provider consolidation. Primary competitors in the Cardiopulmonary and Neuromodulation product groups include Terumo Medical Corporation, Maquet Medical Systems, Medtronic plc, Haemonetics Corporation, Spectrum Medical Limited, and NeuroPace, Inc. The company manufactures most products in the United States, Italy, Germany, Australia, and Brazil, sourcing raw materials globally.
LivaNova Showcases Growth and Strategic Insights at Wolfe Research Healthcare Conference LONDON, October 2023 LivaNova PLC (Nasdaq: LIVN), a prominent player in the medical technology sector, is set to showcase its growth trajectory and strategic direction at the upcoming Wolfe Research Healthcare Conference 2025. The conference will take place on November 17 in New York City, where LivaNova’s CEO, Vladimir Makatsaria, and CFO, Alex Shvartsburg, will engage in a fireside chat. The session is expected to provide key insights into the company’s operational strategies, market presence, and financial performance to a broad audience of investors and stakeholders.As LivaNova prepares for this significant e...
Livanova Plc’s Comment on Sales, Marketing and Customers
LivaNova serves a global customer base that includes perfusionists, neurologists, neurosurgeons, other healthcare professionals, hospitals, and medical institutions. The company collaborates with medical professionals to monitor therapeutic and diagnostic trends and participates in medical conferences and training activities. Hospitals and medical device customers often seek to reduce costs through centralized purchasing and vendor consolidation, resulting in competitive pricing pressures. LivaNova operates in over 100 countries and faces competition from large and small manufacturers, alternative medical therapies, pharmaceuticals, and surgical interventions. Key competitive factors include product efficacy, quality, price, managed care developments, and healthcare provider consolidation. Primary competitors in the Cardiopulmonary and Neuromodulation product groups include Terumo Medical Corporation, Maquet Medical Systems, Medtronic plc, Haemonetics Corporation, Spectrum Medical Limited, and NeuroPace, Inc. The company manufactures most products in the United States, Italy, Germany, Australia, and Brazil, sourcing raw materials globally.
Sources:
Livanova Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Livanova Plc’s corporate clients.
For your research, we’ve provided 9 tables on Livanova Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
110.15 %